NY Governor Announces Plans for $430 Million Biotherapies Hub

New York Governor Kathy Hochul announced plans this week for the New York BioGenesis Park (NYBGP), a $430 million cell and gene therapy innovation hub in Nassau County, Long Island. The state will contribute $150 million to establish the NYBGP, which aims to catalyze CGT research, development, clinical manufacturing and commercialization in New York State and accelerate the delivery of new therapies from lab to patients.

Upon completion, the 700,000-square-foot park will serve as an end-to-end CGT innovation and supply center. It will feature interconnected spaces for public engagement, research, manufacturing and collaboration, as well as an incubator to support early-stage developers with wet lab facilities, shared equipment and office space.

AABB institutional member New York Blood Center Enterprises (NYBCe), through its Comprehensive Cell Solutions (CCS) division, will partner with New York State to establish the NYBGP. CCS will provide expertise and infrastructure as a leading contract development and manufacturing organization (CDMO) and will support pharmaceutical companies, academic institutions and early-stage developers.

“The establishment of the Long Island Center for Cell and Gene Therapy is a pivotal investment in the future of medicine,” said Christopher Hillyer, MD, PhD, “NYBCe and CCS are honored to play a leading role in positioning New York as a global leader in life sciences, particularly in cell and gene therapy, offering hope to patients with diseases once considered untreatable.”